Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.77 |
| ▸ | DRD4 | P21917 | 11/20 | 0.77 |
| ▸ | DRD3 | P35462 | 11/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.77 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201583 | 0.98 | DRD2 (0.75) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL29119406 | 0.98 | DRD2 (0.75) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL6200847 | 0.95 | DRD2 (0.84) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL30483504 | 0.89 | DRD2 (0.69) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL17979351 | 0.89 | DRD2 (0.69) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL10615952 | 0.89 | HTR2A (0.66) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL12307238 | 0.87 | HTR2A (0.64) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL12307218 | 0.87 | HTR2A (0.64) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL12307233 | 0.87 | HTR2A (0.64) | DRD2DRD4DRD3CHRM2CHRM4 | |
| SCHEMBL10844596 | 0.86 | CHRM2 (0.71) | DRD2DRD4DRD3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-0937045-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | Allergan Sales, Inc. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998019999-A1 | N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY | ALLERGAN SALES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | DRD2 757/4885DRD4 945/4885DRD3 716/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | DRD2 876/4885DRD4 1163/4885DRD3 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.